Savient shares crater on adverse events

Shares of Savient Pharmaceuticals cratered after the developer announced that five patients experienced heart problems while taking the drug pegloticase in two trials. Its stock plunged 71 percent on the news, with analysts complaining that the safety data raised a warning flag on the drug's potential. The drug is intended to be the first for treatment naive patients. You'll find the safety data near the end of the release. Release l Report